Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-Derived Allogeneic Cell Therapies

Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four iPSC derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors.